coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk We are all anxiously awaiting
Description
References Harding, J
Researchers and healthcare professionals want to help people who are struggling with excessive thoughts about food, but to do so, they need to identify the specific problem they are addressing
No grupo que recebeu placebo, a queda foi menor, de 0,8%
Additionally, some individuals prefer a slower dosing strategy to reduce discomfort
Came to lose a stone and lost just over that in 12 weeks and even better managed to maintain for last 3 months eating a high amount of calories and averaging 11,000 steps a day
